Is type 2 diabetes an amyloidosis and does it really matter (to patients)?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Insulin resistance and cognitive decline: the metabolic mechanisms linking type 2 diabetes to Alzheimer's disease.Diabetology international · 2025
   Review
2. Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.Nature reviews. Endocrinology · 2025
   Review
3. Ameliorating amyloid aggregation through osmolytes as a probable therapeutic molecule against Alzheimer's disease and type 2 diabetes.RSC advances · 2020
   Article
4. Altered metabolic gene expression in the brain of a triprolyl-human amylin transgenic mouse model of type 2 diabetes.Scientific reports · 2019
   Article
5. The triphenylmethane dye brilliant blue G is only moderately effective at inhibiting amyloid formation by human amylin or at disaggregating amylin amyloid fibrils, but interferes with amyloid assays; Implications for inhibitor design.PloS one · 2019
   Article
6. The receptor for advanced glycation endproducts is a mediator of toxicity by IAPP and other proteotoxic aggregates: Establishing and exploiting common ground for novel amyloidosis therapies.Protein science : a publication of the Protein Society · 2018
   Review
7. Islet Amyloid Polypeptide Membrane Interactions: Effects of Membrane Composition.Biochemistry · 2017
   Article
8. Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics.eLife · 2016
   Article
9. Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology.Journal of diabetes research · 2016
   Review
10. Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions.Journal of the American Chemical Society · 2014
    Article
11. Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity.FEBS letters · 2013
    Review
12. Mechanisms of islet amyloidosis toxicity in type 2 diabetes.FEBS letters · 2013
    Review
13. Aggregation of islet amyloid polypeptide: from physical chemistry to cell biology.Current opinion in structural biology · 2013
    Review
14. Structural similarities and differences between amyloidogenic and non-amyloidogenic islet amyloid polypeptide (IAPP) sequences and implications for the dual physiological and pathological activities of these peptides.PLoS computational biology · 2013
    Article
15. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Drugs · 2011
    Review

Corrections and comments

• Comment on
  Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?2010

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as